Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Song, Soken Nakazawa J ^a   Iwahashi, Mitsuhiro ^b   Tomosugi, Naohisa ^c   Uno, Kazuko ^d   Yamana, Jiro ^b   Yamana, Seizou ^b   Isobe, Tomoyasu ^a   Ito, Hiroki ^a   Kawabata, Hiroshi ^e   Yoshizaki, Kazuyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Higashihiroshima Memorial Hospital   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d Louis Pasteur Center for Medical Research   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYTOKINE; HEPCIDIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; IRON; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; ANTIRHEUMATIC AGENT; FERRITIN; HEPCIDIN 25, HUMAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DRUG SCREENING; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UPREGULATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; U937 CELL LINE;

ADULT; AGED; ANEMIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CELL LINE, TUMOR; FEMALE; FERRITINS; GENE EXPRESSION; HEPCIDINS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884791621     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4323     Document Type: Article

References (31)

1. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289. 10.1056/NEJM199005033221805, 2271017.
2. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004, 116(Suppl 7A):50S-57S.
3. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander?. Arch Intern Med 2003, 163:1400-1404. 10.1001/archinte.163.12.1400, 12824088.
4. Peeters HR, Jongen-Lavrencic M, Raja AN, Ramdin HS, Vreugdenhil G, Breedveld FC, Swaak AJ. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis 1996, 55:162-168. 10.1136/ard.55.3.162, 1010122, 8712878.
5. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999, 92:153-160. 10.1006/clim.1999.4736, 10444359.
6. Means RT, Dessypris EN, Krantz SB. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 1990, 86:538-541. 10.1172/JCI114741, 296757, 2384599.
7. Masson C. Rheumatoid anemia. Joint Bone Spine 2011, 78:131-137. 10.1016/j.jbspin.2010.05.017, 20851655.
8. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, for the ATTRACT Group Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0, 10622295, for the ATTRACT Group.
9. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005, 52:1960-1967. 10.1002/art.21107, 15986340.
10. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167. 10.1136/ard.2006.068064, 1955155, 17485422.
11. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5, 18358926, OPTION Investigators.
12. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002, 100:474-482. 10.1182/blood-2002-01-0136, 12091338.
13. Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum 2009, 39:123-131. 10.1016/j.semarthrit.2008.08.002, 18823645.
14. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810. 10.1074/jbc.M008922200, 11113131.
15. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. A novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480:147-150. 10.1016/S0014-5793(00)01920-7, 11034317.
16. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093. 10.1126/science.1104742, 15514116.
17. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110:1037-1044. 151151, 12370282.
18. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463. 10.1182/blood-2002-10-3235, 12433676.
19. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001, 98:8160-8162. 10.1073/pnas.161296298, 37412, 11459944.
20. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002, 100:3776-3781. 10.1182/blood-2002-04-1260, 12393428.
21. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116:3627-3634. 10.1182/blood-2010-03-271791, 20644113.
22. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276. 398432, 15124018.
23. Kim HR, Kim KW, Yoon SY, Kim SH, Lee SH. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci 2010, 25:348-352. 10.3346/jkms.2010.25.3.348, 2826733, 20191031.
24. Demirag MD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, Goker B. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009, 48:421-426. 10.2169/internalmedicine.48.1578, 19293540.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
26. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769. 10.1002/art.20303, 15188351.
27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
28. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101:4148-4154. 10.1182/blood-2002-08-2459, 12522003.
29. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529. 10.1002/art.11143, 12794819.
30. Brenchley PE. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 2001, 60(Suppl 3):iii71-iii74. 1766681, 11890660.
31. Shanmugam NK, Ellenbogen S, Trebicka E, Wang L, Mukhopadhyay S, Lacy-Hulbert A, Gallini CA, Garrett WS, Cherayil BJ. Tumor necrosis factor α inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis. PLoS One 2012, 7:e38136. 10.1371/journal.pone.0038136, 3365004, 22675442.